-- Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per share. --
Akebia Therapeutics (AKBA) Q4 2019 Earnings Snapshot
Categories
Health Care
Minerva Neurosciences (NASDAQ: NERV): Q4 2019 Earnings Snapshot
-- Minerva Neurosciences Inc. (NASDAQ: NERV) reported a fourth-quarter 2019 loss of $29.9 million or $0.77 per share, wider than a loss
BioXcel Therapeutics (BTAI) Q4 loss widens on higher expenses
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) reported a wider net loss for the fourth quarter, owing to an increase in research and development
Matinas BioPharma (MTNB): Q4 2019 Earnings Snapshot
Image for representation (Photo by Drew Hays on Unsplash) — Matinas BioPharma (NYSE: MTNB) reported loss of $0.04 per share in the fourth quarter
No surprises expected when InspireMD (NSPR) reports Q4 earnings
InspireMD (NYSE: NSPR) has incurred losses consistently over the past several years. Of late, shareholders have been apprehensive about their investments as
Bio-Path Holdings (NASDAQ: BPTH): 2019 Earnings Snapshot
-- Bio-Path Holdings Inc. (NASDAQ: BPTH) reported a loss of $3.24 share for the full year 2019, narrower than a loss of
Aurinia Pharmaceuticals (NASDAQ: AUPH): Q4 2019 Earnings Snapshot
-- Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a fourth-quarter 2019 loss of $0.78 per share versus a loss of $0.14 per share expected.
Stock Analysis: GW Pharma (GWPH) offers irresistible upside potential
For GW Pharmaceuticals (NASDAQ: GWPH), the main growth strategy for the current fiscal year is to expand its product pipeline beyond Epidiolex,
Arbutus Biopharma (ABUS): FY19 Earnings Snapshot
-- Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a
BioCryst Pharmaceuticals (BCRX) Q4 2019 Earnings Snapshot
-- BioCryst Pharmaceuticals (NASDAQ: BCRX) reported a loss of $0.02 per share for the fourth quarter of 2019 vs. expected loss of
AMAG Pharmaceuticals (AMAG) Q4 2019 Earnings Snapshot
-- AMAG Pharmaceuticals (NASDAQ: AMAG) reported a net loss of $199.9 million or $5.89 per share for the fourth quarter of 2019
Tilray Inc (NASDAQ: TLRY) Q4 2019 Earnings Call Transcript
Tilray Inc (NASDAQ: TLRY) Q4 2019 Earnings Conference Call Final Transcript Corporate Participants: Brendan Kennedy -- Chairman, President and Chief Executive Officer Mark Castaneda -- Chief Financial
Amicus Therapeutics (FOLD): FY 2019 Earnings Snapshot
-- Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared
Eagle Pharmaceuticals (NASDAQ: EGRX): Q4 2019 Earnings Snapshot
-- Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) reported its fourth-quarter 2019 adjusted earnings of $0.48 per share versus $0.46 per share expected. --
Cara Therapeutics Inc. (NASDAQ: CARA) Q4 2019 Earnings Call Transcript
Cara Therapeutics Inc (NASDAQ: CARA) Q4 2019 Earnings Conference Call Final Transcript Corporate participants: Jack Hildick-Smith -- Investor Relations Derek Chalmers -- President, Director and Chief Executive
SmileDirectClub (SDC) stock drops to lowest since IPO amid growth prospects
Shares of SmileDirectClub Inc. (NASDAQ: SDC) plunged over 52% to $7.17 on Thursday, which is the lowest since the initial public offering
Sage Therapeutics (SAGE) Q4 2019 Earnings Snapshot
-- Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61. --
ACADIA Pharmaceuticals (ACAD): Q4 2019 Earnings Snapshot
-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected. -- Revenue grew 65% to
Sarepta Therapeutics (SRPT): Q4 2019 Earnings Snapshot
-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.
Moderna (MRNA) ships coronavirus vaccine candidate for trials, shares hit a peak
Shares of Moderna Inc. (NASDAQ: MRNA) soared to a record high of $29.98 on Wednesday after shipping the first coronavirus vaccine candidate
Endo International (NASDAQ: ENDP): Q4 2019 Earnings Snapshot
-- Endo International plc (NASDAQ: ENDP) reported its fourth-quarter 2019 adjusted earnings of $0.74 per share versus $0.57 per share expected. --